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During 2020, as everything else, cancer research has been challenged by the global Covid-19 9 
pandemic (1,2). Although most of the laboratories worldwide had a period of forced stop, still 10 
scientists have found ways to cope and adapt to the rapidly changing circumstances and 11 
remain focused and productive during these challenging times.  12 
Being perfectly aware of the difficulties that investigators have been facing, Cancer Gene 13 
Therapy CGT has adjusted the peer review process accordingly (i) by extending the revision 14 
timelines, (ii) by being realistic in the requests for technically challenging and time-15 
consuming additional experiments and (iii) by demanding to tone down conclusions where 16 
definite supporting data were not available. Despite these conditions, the journal’s priorities 17 
to safeguard the quality and sustain the integrity of the published scientific work were not 18 
affected.  19 
The researchers’ resilience is embodied in the fascinating research that has been published in 20 
CGT over the last year and that has captured the interest of the scientific community. Here, 21 
we highlight some of the Articles that cover different aspects of current cutting-edge research 22 
including the development of organoids as cancer models, novel methods like new drug 23 
delivey systems as well as innovative applications of the zebrafish model.   24 
Identification of new therapeutic targets for AML: One of the goals in cancer research is 25 
discovering oncogenic drivers, that often includes the cancer’s mutational status. However, it 26 
is now well established that the mechanisms that lead to genetic mutations should be 27 
considered pivotal factors in neoplastic transformation. A perfect example of this approach is 28 
the work published by Ruckert et al. AML (Acute Myeloid leukaemia) is a hematopoietic 29 
malignancy with poor prognosis, particularly in the elderly population (3). HUWE1, an E3 30 
ubiquitin ligase involved in several cell processes, was identified to be the second most 31 
expressed gene in AML, according to a TCGA-based analysis. Using leukemia cells 32 
constitutively expressing mutated RAS  (KRASG12V), the authors identified a mechanism by 33 
which HUWE1 cooperates with mutated RAS activation and controls proliferation of cancer 34 
cells. In addition, in silico analysis highlighted that expression of HUWE1 correlates with 35 
myeloid differentiation related genes. Their findings suggest that HUWE1 is not only 36 
involved in controlling RAS mutated AML cell proliferation but it could also be implicated in 37 
myeloid differentiation (4).  38 
Signature of AML stem cells: Another challenge in AML research is to identify new genetic 39 
signatures able to detect AML-specific stem cells that are responsible for tumor relapse and 40 
therapy resistance (5). An alternative bioinformatic approach has been employed by Li et al. 41 
In their manuscript, using Monte Carlo feature selection combined with machine learning 42 
algorithms, the authors developed a method to identify gene expression features that are 43 
specific for stem cells. The identified genes (n=17) can be considered as specific biomarkers 44 
of leukaemia stem cells and may have a fundamental impact on future research and therapy 45 
design (6).  46 
 47 
Ferroptosis, a new pathway of cell death: Cell signalling that regulates cell death has been 48 
the central core of cancer drug discovery for decades. Along with necrosis and apoptosis, it is 49 
currently known that cells can use several alternative routes to trigger cell death (7). In recent 50 
years, another type of programmed cell death, namely ferroptosis, has been described, which 51 
is accompanied by a large amount of iron accumulation and lipid peroxidation (8).  52 
The review by Dai et al., describes in a thorough and comprehensive way the transcription 53 
factors involved in ferroptosis that can be targeted in different cancer types (9). The same 54 
group has also studied autophagy dependent ferroptosis. Inhibition of the mammalian target 55 
of rapamycin kinase (mTOR) with rapamycin is used to trigger autophagy (10). The authors 56 
identified a role for peroxidase 4 (GPX4), an antioxidant enzyme, in modulating autophagy 57 
dependent ferroptosis in pancreatic cancer cells. The results demonstrated that treatment with 58 
rapamycin induces GPX4 degradation and consequently ferroptosis. In addition, researchers 59 
found that genetic silencing of GPX4 was sufficient to trigger autophagy dependent 60 
ferroptosis (11).  These findings shed light on the mechanisms of stress response during cell 61 
death and suggest possible targets for cancer therapy. 62 
 63 
A central role for PI3K in cancer research: The critical role of the PI3K/AKT/mTOR 64 
pathway in cancer has been demonstrated by several studies (12). However, the role of PIK3 65 
as a prognostic tool in advanced malignancies has not been fully demonstrated. In the review 66 
by Willis et al., the authors analysed the role of PIK3CA mutations in cancer and patient 67 
management (13) and conclude that future PIK3CA-targeted therapy will rely on a better 68 
understanding of the PI3K/AKT/mTOR signalling pathway, and on the development  of 69 
target-specific inhibitors.  70 
 71 
Oncolytic Viruses, new frontiers for cancer treatment: Oncolytic Viruses (OVs) are the object 72 
of intense research in both basic science and clinical trials. OVs should infect malignant cells, 73 
albeit not all the mechanisms and strategies that can drive this selectivity have been 74 
elucidated. Hulin-Curtis and co-authors identified several peptides that bind to Folate 75 
Receptor α (FRα) as a potential way to target the delivery of human adenoviral oncolytic 76 
virotherapies.  FRα is a membrane protein involved in folate metabolism, with relatively low 77 
expression in normal cells, which is however upregulated in cancer cells (14). The identified 78 
FRα−binding peptides were genetically introduced in human adenoviruses and showed 79 
specificity for cancer cells in vivo. This study represents a promising starting point for 80 
improving targeted OVs, however the study did not improve the delivery of OVs carryng the 81 
peptides sequences to  cancer cells, compared to wild type OVs (15). 82 
 83 
Adapting Zebrafish to create a flexible model for cancer research: On the same topic, 84 
Mealiea et al., set up an interesting experimental system to monitor the effects of OVs by 85 
adapting a zebrafish tumor xenograft model. By exploiting the transparency of zebrafish 86 
during the embryonic stage and by combining different zebrafish strains harboring 87 
fluorescent immune and endothelial cells, the authors were able to investigate in real-time 88 
important events, such as angiogenesis and tumor formation, related to tumour formation and 89 
also associated to how tumours respond to OVs treatment (16). This system may represent a 90 
useful model for future OVs research and therapy design.   91 
 92 
Organoids, tumor in a dish: Using adequate models to identify new therapeutic molecules 93 
that can control tumor growth is of fundamental importance. Tumor organoids can be used to 94 
recapitulate in vitro the pathological features of a disease, including its response to treatment. 95 
With this in mind, Chen et al., set up an organoid-based drug screening assay to identify 96 
inhibitors for the treatment of endometrial cancer. The authors screened a small library of 97 
molecules targeting epigenetic factors. They identified menin-MLL inhibitors that were able 98 
to reduce the growth of mouse organoids. MEN1 gene was found to be upregulated in 99 
endometrial cancer and MEN1 levels correlated with poor prognosis (17), suggesting it as a 100 
potential new target for endometrial cancer treatment.  101 
 102 
Manipulating immune cells to improve cancer therapy: Another useful tool for targeting 103 
cancer cells are the chimeric antigen receptors (CARs) that make T lymphocytes tumor 104 
specific. CAR-T cells have shown promising results and have been recently approved by 105 
FDA and EMA for lymphoma and leukemia treatment (18). However, there are still several 106 
issues that need to be addressed before this approach could see wider application. In the work 107 
by Papathanasiou et al., the authors described the challenges and opportunities behind this 108 
therapeutic approach (19). 109 
 110 
Methods to overcome drug resistance: Despite the overall progress, there are still cancer 111 
types for which medical therapy remains extremely challenging, due to the lack of 112 
appropriate targeting molecules and/or because of intrinsic and acquired resistance processes. 113 
A perfect example of such malignancies are the Neuroendocrine tumors (NETs), a relatively 114 
rare disease arising from the neuroendocrine cells spread in the normal epithelium (20).  Si et 115 
al., aimed to develop an antibody-drug conjugated (ADC) to treat NETs. As a result, they 116 
produced an antibody conjugated with antimitotic auristatin E that was able to target the two 117 
extracellular domains of the somatostatin receptor 2 (SSTR2), which has strong specificity 118 
for NET cells, promoting their death. Ultimately, this new approach might be used to 119 
improvethe therapeutic management of NETs in the clinic(21).   120 
 121 
Overall, despite the unprecedented difficultiesthat have shaped 2020, it is remarkable and 122 
encouraging to witness the continuous and fruitful efforts of cancer researchers and scientists 123 
around the world who remain committed to scientific excellence. 124 
 125 
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